Compare FGI & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGI | HIND |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Industrial Specialties | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 15.2M |
| IPO Year | 2021 | 2016 |
| Metric | FGI | HIND |
|---|---|---|
| Price | $7.78 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $10.00 | $8.83 |
| AVG Volume (30 Days) | ★ 8.6K | 8.5K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | ★ $319,714.00 |
| Revenue This Year | $3.45 | N/A |
| Revenue Next Year | $5.39 | $82.65 |
| P/E Ratio | $49.53 | ★ N/A |
| Revenue Growth | N/A | ★ 24.43 |
| 52 Week Low | $3.14 | $1.62 |
| 52 Week High | $19.93 | $6.56 |
| Indicator | FGI | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 50.47 |
| Support Level | $6.64 | $1.82 |
| Resistance Level | $8.23 | $2.31 |
| Average True Range (ATR) | 0.59 | 0.10 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 54.48 | 53.17 |
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, it generates the majority of its revenue from the United States, followed by Canada and Europe.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.